Phathom Pharmaceuticals Inc (NASDAQ:PHAT) price on Thursday, March 20, rose 2.96% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $6.26.
A look at the stock’s price movement, the close in the last trading session was $6.08, moving within a range at $5.935 and $6.31. The beta value (5-Year monthly) was 0.636. Turning to its 52-week performance, $19.71 and $4.07 were the 52-week high and 52-week low respectively. Overall, PHAT moved 8.68% over the past month.
Phathom Pharmaceuticals Inc’s market cap currently stands at around $435.93 million, with investors looking forward to this quarter’s earnings report slated for on 2025-Mar-05.
Analysts have a consensus estimate of 27.91M for the company’s revenue for the quarter, with a low and high estimate of 24.74M and 31.5M respectively. The average forecast suggests up to a 1,359.83% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 163.67M, representing a 196.23% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that PHAT is a 50% Sell. On the other hand, the stock is on average a 50% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
10 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 2 analyst(s) rate the stock as a Hold, 6 recommend PHAT as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 2 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
PHAT’s current price about 16.98% and 5.59% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 57.59, while 7-day volatility ratio is 11.58% and 11.73% in the 30-day chart. Further, Phathom Pharmaceuticals Inc (PHAT) has a beta value of 0.38, and an average true range (ATR) of 0.60. Analysts have given the company’s stock an average 52-week price target of $18, forecast between a low of $18 and high of $18. Looking at the price targets, the low is -187.54% off current price level while to achieve the yearly target high, price needs to move -187.54%. Nonetheless, investors will most likely welcome a -187.54% jump to $18 which is the analysts’ median price.
If we refocus on Phathom Pharmaceuticals Inc (NASDAQ:PHAT), historical trading data shows that trading volumes averaged 1.62 over the past 10 days and 1.12 million over the past 3 months. The company’s latest data on shares outstanding shows there are 68.52 million shares.
The 44.52% of Phathom Pharmaceuticals Inc’s shares are in the hands of company insiders while institutional holders own 60.21% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 13.92 million on 2025-02-28, giving us a short ratio of 13.68. The data shows that as of 2025-02-28 short interest in Phathom Pharmaceuticals Inc (PHAT) stood at 2865.0 of shares outstanding, with shares short falling to 14.63 million registered in 2025-01-31. Current price change has pushed the stock -22.91% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the PHAT stock continues to rise going into the next quarter.
